Voyager Therapeutics to Showcase at Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology firm focused on advancing neurogenetic therapies, has announced its participation in several upcoming investor conferences. These events aim to highlight the company's innovative research and development efforts in treating neurological diseases.
Details on Upcoming Conferences
Voyager will connect with investors at two significant events:
- The Wells Fargo 2024 Healthcare Conference in Boston, which will feature a fireside chat on September 5, 2024, at 1:30 p.m. ET.
- The Baird 2024 Global Healthcare Conference in New York City, where another fireside chat is scheduled for September 11, 2024, at 1:25 p.m. ET.
Webcasts of these presentations will be accessible in the Investors section of Voyager’s website, allowing a wider audience to engage with this important information. Additionally, a replay of the webcasts will be available for at least 30 days after the events.
About Voyager Therapeutics
Voyager Therapeutics, Inc. is a leader in biotechnology, dedicated to utilizing human genetics to create therapies that aim to alter the progression of neurological diseases and ultimately find cures. Their research pipeline features cutting-edge programs targeting conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other disorders impacting the central nervous system.
Innovative Research and Development
The company's progress is driven by its TRACER™ AAV capsid discovery platform, which has been instrumental in developing novel capsids and identifying related receptors. These advancements are expected to improve the delivery of genetic medicines directly to the brain through intravenous dosing, thereby enhancing treatment effectiveness for patients with neurodegenerative diseases.
Collaborations and Partnerships
Voyager Therapeutics collaborates with esteemed partners such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc. These partnerships not only bolster Voyager’s capabilities but also strengthen its position in the competitive biotechnology arena.
Investor Engagement and Future Outlook
The upcoming conferences present a valuable chance for Voyager Therapeutics to engage with investors and share updates on its ongoing projects and future plans. As the neurogenetics field evolves, Voyager remains dedicated to leading the development of transformative therapies that can significantly improve the lives of patients dealing with debilitating neurological conditions.
Contact Information
For further inquiries, Voyager Therapeutics encourages communication through the following contacts:
Trista Morrison, NACD.DC
Email: tmorrison@vygr.com
Investors: Adam Bero, Ph.D.
Email: abero@kendallir.com
Media: Brooke Shenkin
Email: brooke@scientpr.com
Frequently Asked Questions
What conferences is Voyager Therapeutics attending?
Voyager Therapeutics will be present at the Wells Fargo 2024 Healthcare Conference and the Baird 2024 Global Healthcare Conference, both of which will include fireside chats.
What technologies does Voyager Therapeutics use?
Voyager Therapeutics employs its TRACER™ AAV capsid discovery platform to improve the delivery of genetic medicines aimed at neurological diseases.
Which neurological diseases is Voyager Therapeutics focusing on?
The company is working on treatments for neurological diseases such as Alzheimer's, ALS, and Parkinson’s disease.
Who are Voyager Therapeutics' partners?
Voyager's key partners include Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc.
How can investors contact Voyager Therapeutics?
Investors can reach out via email to Adam Bero, Ph.D., at abero@kendallir.com.